medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2001, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2001; 10 (2)

Assessment of Klebsiella pneumoniae glycoprotein efficacy in recurrent infections

Saracho Wf, Vázquez Rv, Ayala Bc

Language: Spanish
References: 22
Page: 33-39
PDF size: 354.84 Kb.


ABSTRACT

The therapy based on immune stimulation represents a good alternative to prevent and reduce the infectious episodes of the respiratory tract. Klebsiella pneumoniae glycoproteins extracts have an immunostimulant action, since they work at the antibodies synthesis level, in the humoral immunity and the phagocytosis. An open, multicentric, comparative, randomised, double blind trial with placebo was carried out. The treatment was administered for 8 consecutive days in a month, during 3 months, at doses of 2 capsules of K. pneumoniae glycoprotein of 1 mg per day, or placebo, the patients were evaluated at intervals of three, nine and twelve months. Five hundred twenty four subjects (female and male) were included in the trial, in two groups: children and young people (above 2 years and below 18 years old) and adults (above 18 years old). The results showed that the patients treated with K. pneumoniae glycoprotein extract had a statistically significant reduction (p ≤ 0.05) in relation with the group that was treated with placebo, in the following evaluated symptoms: Average in the number and duration of the infectious episodes, in the number of treatments with antibiotics, dysphagia, body temperature, nasal secretion, cough, pain, purulent expectoration volume and the mebrane tympanic aspect. The immunotherapy based on K. pneumoniae glycoproteins extract showed major efficacy in the group of children and young people.


REFERENCES

  1. Voisin C. L estimulation des défenses inmunitaries de láppareil respiratorie. Sem Hop Paris 1982: 251-53.

  2. Secretaría de Salud. Anuario Estadístico México, 1998.

  3. Secretaría de Salud. Mortalidad 1998

  4. Lode H. Respiratory infection: the disease. Clin Ther 1985; 7: 149-241.

  5. Gialdroni G and Grassi C. Bacterial products as immunomodulating agents. Int Arch Allergy Appl Inmun 1985; 76(suppl.1): 119-127.

  6. Semets P, Zalizs R and Boisnic F. Biostim (RU 41740), immune functions and infections. Prod Int Sym. Immunomodulators and non-specific host defense mechanisms against microbial infections. Berlin. Pargamon Press, Adv Biosc 1987; 68. 85-102.

  7. Fauci AS, Risenberg SA and Sherwin SA. Immunomodulators in clinical medicine. Ann Inter Med 1987;106: 421-433.

  8. Bruvier C, Montreuil J, Fournet B et al. Study of a glycoprotein possessing an immunostimulant activity isolated from Klebsiella pneumoniae (abstract). International Congress on Glycoconjugates, Viena, 1981.

  9. Marin C. Glycoprotein extraites de Klebsiella pneumoniae: Réactivatur inmunitarie global théorie et practique 1982; 24: 75-89.

  10. Nielsen H and Bonce J. Immunostimulation of blood monocyte function by RU 41740 (Biostim) in patients with chronic bronchitis. Ints L Immunopharmacol 1986; 8: 589-592.

  11. Bruvier JF. Increased alveolar neutrophil count and superoxide anion generation after oral administration of Ru 41740 5th International Congress of Immunology, Kyoto 1983.

  12. Griscelli C, Grospierre B, Mintreul J. Immunomodulation by glycoprotein fractions isolated from Klebsiella pneumoniae. En Yamura Y Kiotoni S (eds.) Immunomodulations by microbial products and related synthetic compound. Excerp Medica, Amsterdam. 1982: 261-65

  13. Guenounnou M, Smets P, and Agneray J. Immunomodulating activity of RU 41740, a glycoprotein extract from Klebsiella pneumoniae. Farm Ter 1985; 1: 28-32.

  14. Wood Cd and MôllerG. Influence of RU 41740, a glycoprotein extract from Klebsiella pneumoniae on the murine system I.- T-independent polyclonal B cell activation. J Immunol 1984; 132(2): 616-21.

  15. Bonfis P. Prophylaxie des infections des voies respiratories chez lènfant par le RU41740. La Presse Mëdicale 1988; 17: 1450-52.

  16. Duhamel JF and Onuis I. Utilization du Biostim dnas les infectios repiratories récidivantes de lénfant. Etude en double insu deux formes galéniques orasles. Rev Intern Pediatrie 1990; 198: 67-72.

  17. Ramos J J. Estudio aleatorio doble ciego sobre eficacia de Biostim versus placebo en el tratamiento de infecciones respiratorias bajas en adultos. International Congress of Chemotherapy. Estocolmo. 1993.

  18. Espinosa RF, Orozco MS, Berrón PR. Modulares de la respuesta inmune. Alerg Asma Inmunol Pediatr 1996; 5: 89-94.

  19. Viallat JR, Costantini D, Boutin C et al. Etude en double aveyle dún inmunomodulateur dórigine bactérienne (Biostim) dans la prevention des épisodes infectieux chez bronquitique cronique. Pomon Coeur 1983: 39-53.

  20. Marin C. Glycoprotein extraites de Klebsiella pneumoniae: Réactivatur inmunitarie global théorie et practique. 1982; 24: 75-89.

  21. Viallat JR, Costantini D, Boutin C et al. Etude en doble aveyle d’un inmunomodulateur d’origine bactérienne (Biostim) dans la prevention des épisodes infectieux chez le bronchitique chronique. Pomo Coeur 1983; 39: 53.

  22. O´connor D, Cordell R, Pickering L. Infecciones frecuentes en estancias infantiles. Atención Médica 1998:. 14-27.




2020     |     www.medigraphic.com